

SEARCH REQUEST FORM
119634

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Edward Woo Examiner #: 67450 Date: APR 18, 2004
Art Unit: 1634 Phone Number 305-272-0881 Serial Number: 10600392
Mail Box and Bldg/Room Location: 3014 Results Format Preferred (circle) PAPER DISK E-MAIL
Renss M.E.J.

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): Lee, Hyong Woo

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

SEARCHED
INDEXED
SERIALIZED
FILED
(STC)

STAFF USE ONLY

Point of Contact:	Type of Search	Vendors and cost where applicable
Searcher: <u>Alexandra Wadlawiw</u>	NA Sequence (#)	STN <u>\$325</u>
Searcher Phone <u>Technical Info. Specialist</u> <u>OM1-6A02 TEL 308-4491</u>	AA Sequence (#)	Dialog _____
Searcher Location <u>Renf 1A1 2-2534</u>	Structure (#)	Questel/Orbit _____
Date Searcher Picked Up: <u>4-19-04</u>	Bibliographic	Dr. Link _____
Date Completed: <u>4-19-04</u>	Litigation	Lexis/Nexis _____
Searcher Prep & Review Time: <u>14</u>	Fulltext	Sequence Systems _____
Clerical Prep Time: _____	Patent-Family	WWW/Internet _____
Online Time: <u>35</u>	Other	Other (specify) _____

28



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 119634

TO: Edward Ward
Location: REM/3D14/3D11
Art Unit: 1654
Monday, April 19, 2004

Case Serial Number: 10/600392

From: Alex Waclawiw
Location: Biotech-Chem Library
Rem 1A71
Phone: 272-2534

E-mail: Alexandra.waclawiw@uspto.gov

Search Notes

Ward 10/10/600392

=> d his

(FILE 'REGISTRY' ENTERED AT 14:09:32 ON 19 APR 2004)
DEL HIS Y
ACT WARD2/A

L1 STR
L2 (30)SEA FILE=REGISTRY SSS FUL L1
L3 STR
L4 24 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

L5 24 S L4 AND (USPATFULL)/LC
L6 24 S L4 AND (CA OR CAPLUS)/LC
L7 0 S L5 NOT L6
L8 0 S L4 NOT (L5 OR L6)

FILE 'CAPLUS' ENTERED AT 14:11:18 ON 19 APR 2004
L9 6 S L4

Ward 10/10/600392

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:11:31 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9
DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que stat 14
L1 STR



Page 1-A

CH₂-Me
4 16

Page 1-B


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

Ward 10/10/600392

STEREO ATTRIBUTES: NONE

L2 (30) SEA FILE=REGISTRY SSS FUL L1
L3 STR



Page 1-A

CH2—Me
4 16

Page 1-B

VAR G1=C/N

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L4 24 SEA FILE=REGISTRY SUB=L2 SSS FUL L3

100.0% PROCESSED 26 ITERATIONS
SEARCH TIME: 00.00.02

24 ANSWERS

=> fil caplus
FILE 'CAPLUS' ENTERED AT 14:11:37 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

Ward 10/10/600392

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17
FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


'OBI' IS DEFAULT SEARCH FIELD FOR 'CPLUS' FILE

```
=> d que nos 19
L1      STR
L2  (  30) SEA FILE=REGISTRY SSS FUL L1
L3      STR
L4      24 SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L9      6 SEA FILE=CPLUS ABB=ON PLU=ON L4
```

=> d .ca hitstr 19 1-6

L9 ANSWER 1 OF 6 CPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:319478 CPLUS
DOCUMENT NUMBER: 138:287984
TITLE: Preparation of apicidin-derived cyclic tetrapeptides
INVENTOR(S): Meinke, Peter T.; Schmatz, Dennis; Myers, Robert W.;
Rattray, Sandra J.; Colletti, Steven L.; Wyvratt,
Matthew J.; Fisher, Michael H.; Gurnett, Anne M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of U.S.
Ser. No. 614,793.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078369	A1	20030424	US 2002-66451	20020131
PRIORITY APPLN. INFO.:			US 1999-145329P	P 19990723
			US 2000-614793	A2 20000712
OTHER SOURCE(S):	MARPAT 138:287984			
GI				



AB Cyclic tetrapeptide compds. I [X = CH₂, CO, CHOH, alkoxy- or aryloxymethylene, etc., :CH, or not present; Y = (CH₂)_n, where n = 1 or 2; R₁ = H, alkyl, aryl, acyl, CN, CO₂H or ester, carboxamido, etc.; R₂ = (un)substituted alkyl, alkenyl, or alkynyl, alkoxy, alkoxyalkyl; R₃ = H, halo, OH, alkoxy, aryloxy, etc., alkyl, aryl; R₅ = iso-Pr, sec-butyl; R₆ = O, S, H₂ (with provisos)] derived from apicidin were prepared for therapeutic inhibition of histone deacetylase activity. Thus, treating 300 mg apicidin with 18 mg NaBH₄ in MeOH and stirring 4 h at room temperature afforded carbonyl reduction product cyclo(N-O-methyl-L-Trp-L-Ile-D-Pip-L-2-amino-8-hydroxydecanoyl) (pip = pipecolic acid residue).

IC ICM C07K007-54
ICS C07D245-00

NCL 530317000; 540460000

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 7

IT	189337-30-2P	189337-32-4P	312956-80-2P	312956-81-3P	312956-82-4P
	312956-83-5P	312956-86-8P	312956-88-0P	312956-90-4P	312956-91-5P
	312956-92-6P	312956-95-9P	312956-96-0P	312956-97-1P	312957-00-9P
	312957-05-4P	314058-15-6P	314058-18-9P	314058-19-0P	
	314058-20-3P	314058-22-5P	314058-23-6P	314058-24-7P	
	314058-27-0P	315189-83-4P	315189-84-5P	315189-87-8P	315189-92-5P
	315189-93-6P	315189-94-7P	315189-95-8P	315189-96-9P	315189-97-0P
	315189-99-2P	315190-03-5P	315190-04-6P	315190-05-7P	315190-06-8P
	315190-07-9P	315190-11-5P	315190-12-6P	315190-13-7P	315190-14-8P
	321798-41-8P	321798-61-2P	321798-68-9P	321798-73-6P	321798-87-2P
	322000-66-8P	322000-67-9P	322000-68-0P	322000-69-1P	
	322000-70-4P	322000-72-6P	322000-73-7P	322000-74-8P	322000-75-9P
	322000-76-0P	322000-80-6P	322000-82-8P	322000-84-0P	322000-86-2P
	322000-87-3P	322000-88-4P	322000-89-5P	322000-91-9P	322000-92-0P
	322000-93-1P	322000-94-2P	322000-95-3P	322000-97-5P	322000-98-6P
	322000-99-7P	322001-00-3P	322001-01-4P	322001-03-6P	322001-05-8P
	322001-07-0P	322001-09-2P	322001-12-7P	322001-13-8P	322001-15-0P
	322001-18-3P	322001-19-4P	322001-23-0P	322001-25-2P	322001-26-3P
	322001-29-6P	322001-31-0P	322001-32-1P	322001-33-2P	322001-34-3P
	322001-35-4P	322001-36-5P	322001-39-8P	322001-41-2P	322001-42-3P
	322001-44-5P	322001-45-6P	322001-46-7P	322001-47-8P	322001-48-9P
	322001-50-3P	322001-51-4P	322001-52-5P	322001-53-6P	322001-54-7P
	322001-55-8P	322001-56-9P	322001-59-2P	322001-60-5P	322001-61-6P
	322001-62-7P	322001-63-8P	322001-64-9P	322001-65-0P	322001-66-1P
	322001-67-2P	322001-70-7P	322001-71-8P	322001-73-0P	322001-74-1P
	322001-75-2P	322001-76-3P	322001-77-4P	322001-78-5P	
	322001-79-6P	322001-80-9P	322001-81-0P	322001-82-1P	
	322001-83-2P	322001-84-3P	322001-85-4P	322001-86-5P	322001-87-6P
	322001-88-7P	322001-92-3P	322001-94-5P	322001-95-6P	322001-96-7P
	322002-00-6P	322002-01-7P	322002-02-8P	322002-03-9P	322002-04-0P
	322002-07-3P	322002-09-5P	322002-10-8P	322002-11-9P	322002-12-0P
	322002-13-1P	322002-14-2P	322002-15-3P	322002-16-4P	322002-17-5P
	322002-18-6P	322411-12-1P	322411-13-2P		

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of apicidin-derived cyclic tetrapeptides)


IT 314058-20-3P 322000-66-8P 322000-67-9P
322001-77-4P 322001-78-5P 322001-79-6P
322001-80-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of apicidin-derived cyclic tetrapeptides)

RN 314058-20-3 CAPLUS

Ward 10/10/600392

CN Cyclo[(2S)-2-amino-8-methylenedecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidin carbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 322000-66-8 CAPLUS

CN Cyclo[(2S)-2-amino-8-(hydroxyimino)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidin carbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322000-67-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylmethoxy)imino]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidin carbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322001-77-4 CAPLUS


CN Cyclo[(2S)-2-amino-8-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinocarbonyl]
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




RN 322001-78-5 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(carboxymethoxy) imino]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322001-79-6 CAPLUS

CN Cyclo[(2S)-2-amino-8-(methoxyimino)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.




Ward 10/10/600392

RN 322001-80-9 CAPLUS
CN Cyclo[(2S)-2-amino-8-[[[4-(2,3,6,7,12,13,16,17-octahydro-1H,5H,11H,15H-xantheno[2,3,4-ij:5,6,7-i'j']diquinolizin-18-i um-9-yl)-3-sulfophenyl]sulfonyl]hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl], inner salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:504791 CAPLUS
DOCUMENT NUMBER: 137:79231
TITLE: Preparation and formulation of apicidin derivatives
for use as antitumor agents
INVENTOR(S): Lee, Hyang Woo; Jung, Young Hoon; Han, Jeung Whan;
Lee, Seok Yong; Lee, Yin Won; Lee, Hoi Young; Zee, Ok

Ward 10/10/600392

Pyo
PATENT ASSIGNEE(S) : S. Korea
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051846	A1	20020704	WO 2001-KR2228	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004014647	A1	20040122	US 2003-600392	20030620
PRIORITY APPLN. INFO.:			KR 2000-80180	A 20001222
			WO 2001-KR2228	A1 20011221
OTHER SOURCE(S) :	CASREACT 137:79231; MARPAT 137:79231			
GI				



AB Apicidin derivs. I [X = semicarbazone, thiosemicarbazone, hydrazone, tert-butylhydrazone, phenylhydrazone, 2,4-dinitrophenylhydrazone, 4-methoxyphenylhydrazone, 3-methoxyphenylhydrazone, 4-nitrophenylhydrazone, benzylhydrazone, methanesulfonylhydrazone, benzenesulfonylhydrazone, 4-methylbenzenezulfonylhydrazone, benzoylhydrazone, 4-nitrobenzoylhydrazone, carbohydrazone, benzyloxime, acetoxime] were prepared for pharmaceutical use in the treatment of cancer. Thus, apicidin Ia I (X = O), which was obtained via a fermentation process, was reacted with semicarbazide hydrochloride using Et₃N in methanol to give apicidin Ia semicarbazone I (X = NNHCONH₂) in 85.3% yield. The prepared apicidin derivs. were tested for inhibition of histone deacetylase and growth of cancer cells.

IC ICM C07D487-04

CC 34-3 (Amino Acids, Peptides, and Proteins)

Ward 10/10/600392

Section cross-reference(s): 1, 16, 63

IT 322000-66-8P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation and formulation of apicidin derivs. for use as antitumor agents)

IT 322000-67-9P 439859-08-2P, Apicidin Ia semicarbazone

439859-09-3P 439859-10-6P 439859-11-7P
439859-12-8P 439859-13-9P 439859-14-0P
439859-15-1P 439859-16-2P 439859-17-3P
439859-18-4P 439859-19-5P 439859-20-8P
439859-21-9P 439859-22-0P 439859-23-1P
439859-24-2P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and formulation of apicidin derivs. for use as antitumor agents)

IT 322000-66-8P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation and formulation of apicidin derivs. for use as antitumor agents)

RN 322000-66-8 CAPLUS

CN Cyclo[(2S)-2-amino-8-(hydroxyimino)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidin carbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



IT 322000-67-9P 439859-08-2P, Apicidin Ia semicarbazone

439859-09-3P 439859-10-6P 439859-11-7P
439859-12-8P 439859-13-9P 439859-14-0P
439859-15-1P 439859-16-2P 439859-17-3P
439859-18-4P 439859-19-5P 439859-20-8P
439859-21-9P 439859-22-0P 439859-23-1P
439859-24-2P

RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

Ward 10/10/600392

PREP (Preparation); USES (Uses)


(preparation and formulation of apicidin derivs. for use as antitumor agents)

RN 322000-67-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylmethoxy)imino]decanoylethyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-08-2 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(aminocarbonyl)hydrazone]decanoylethyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-09-3 CAPLUS

CN Cyclo[(2S)-2-amino-8-hydrazonodecanoylethyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-10-6 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(1,1-dimethylethyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-11-7 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(hydrazinocarbonyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-12-8 CAPLUS

CN Cyclo[(2S)-8-[(acetyloxy)imino]-2-aminodecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-13-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(aminothioxomethyl)hydrazono]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-14-0 CAPLUS

CN Cyclo[(2S)-2-amino-8-(phenylhydrazone)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-15-1 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(2,4-dinitrophenyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-16-2 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(4-methoxyphenyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-17-3 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(3-methoxyphenyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-18-4 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(4-nitrophenyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-19-5 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylmethyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-20-8 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(methylsulfonyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-21-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylsulfonyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-22-0 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(4-methylphenyl)sulfonyl]hydrazono]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 439859-23-1 CAPLUS

CN Cyclo[(2S)-2-amino-8-(benzoylhydrazono)]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 439859-24-2 CAPLUS
 CN Cyclo[(2S)-2-amino-8-[(4-nitrobenzoyl)hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:34206 CAPLUS
 DOCUMENT NUMBER: 136:232540
 TITLE: Structure and Chemistry of Apicidins, a Class of Novel Cyclic Tetrapeptides without a Terminal α -Keto Epoxide as Inhibitors of Histone Deacetylase with Potent Antiprotozoal Activities
 AUTHOR(S): Singh, Sheo B.; Zink, Deborah L.; Liesch, Jerrold M.; Mosley, Ralph T.; Dombrowski, Anne W.; Bills, Gerald F.; Darkin-Rattray, Sandra J.; Schmatz, Dennis M.; Goetz, Michael A.
 CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Journal of Organic Chemistry (2002), 67(3), 815-825
 CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:232540
 GI



AB Apicidins I [R = Et, R1 = OMe, R2 = CH₂COEt; R = Et, R1 = H, R2 = CH₂COEt; R = Me, R1 = OMe, R2 = CH₂COEt; R = Et, R1 = OMe, R2 = CH₂COCH(OH)Me; R = Et, R1 = OMe, R2 = CH₂CH(S-OH)Et; R = Et, R1 = OMe, R2 = CH₂CH₂CH(OH)Me] are a class of cyclic tetrapeptides that do not contain the classical electrophilic α -keto epoxide and yet are potent (nM) inhibitors of histone deacetylase and antiprotozoal agents. I showed broad-spectrum activities against the apicomplexan family of protozoa including Plasmodium sp (malarial parasite), Toxoplasma gondii, Cryptosporidium sp., and Eimeria sp. These cyclic peptides contain a β -turn amino acid (R)-Pip or (R)-Pro, (S)-N-methoxytryptophan, (S)-Ile or (S)-Val, and either (S)-2-amino-8-oxodecanoic acid or a modified (S)-2-amino-8-oxodecanoic acid. The isolation and structure elucidation of new apicidins from two Fusarium species, temperature-dependent NMR studies of apicidin, NMR and mol. modeling based conformation of the 12-membered macrocyclic ring, and selected chemical modifications of apicidin have been detailed in this paper. The cyclic nature of the peptide, the C-8 keto group, and the tryptophan are all critical for the biol. activity.

CC 34-3 (Amino Acids, Peptides, and Proteins)

IT Section cross-reference(s): 1, 7, 16

IT 314058-18-9P 322000-67-9P 322000-72-6P 403501-69-9P
 403501-70-2P 403501-71-3P 403501-72-4P 403501-73-5P 403501-74-6P
 403501-75-7P 403501-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activity of apicidin derivs. as inhibitors of histone deacetylase with potent antiprotozoal activities)

IT 322000-67-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activity of apicidin derivs. as inhibitors of histone deacetylase with potent antiprotozoal activities)

RN 322000-67-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylmethoxy)imino]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:83649 CAPLUS

DOCUMENT NUMBER: 134:289954

TITLE: Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1

AUTHOR(S): Colletti, S. L.; Myers, R. W.; Darkin-Rattray, S. J.; Gurnett, A. M.; Dulski, P. M.; Galuska, S.; Allococo, J. J.; Ayer, M. B.; Li, C.; Lim, J.; Crumley, T. M.; Cannova, C.; Schmatz, D. M.; Wyvatt, M. J.; Fisher, M. H.; Meinke, P. T.

CORPORATE SOURCE: Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, 07065, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(2), 107-111

CODEN: BMCL8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Apicidin, a natural product recently isolated at Merck, inhibits both mammalian and protozoan histone deacetylases (HDACs). The conversion of apicidin, a nanomolar inhibitor of HDACs, into a series of side-chain analogs that display picomolar enzyme affinity is described within this structure-activity study.

CC 1-3 (Pharmacology)

Section cross-reference(s): 7, 10, 26, 27

IT 312956-79-9 312956-84-6 312956-86-8 312956-88-0 312956-89-1
312956-90-4 312956-91-5 312956-92-6 312956-95-9 312956-96-0
312957-00-9 312957-01-0 312957-03-2 312957-04-3 314058-18-9
314058-19-0 314058-20-3 314058-23-6 314058-24-7
314058-25-8 314058-27-0 322000-77-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiprotozoal activity and histone deacetylase inhibition by apicidin analogs)

IT 314058-20-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES


(Uses)

(antiprotozoal activity and histone deacetylase inhibition by apicidin analogs)

RN 314058-20-3 CAPLUS

CN Cyclo[(2S)-2-amino-8-methylenedecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:78233 CAPLUS
 DOCUMENT NUMBER: 134:131817
 TITLE: Preparation of apicidin-derived cyclic tetrapeptides
 INVENTOR(S): Meinke, Peter T.; Schmatz, Dennis; Fisher, Michael H.; Rattray, Sandra J.; Colletti, Steven L.; Wyvratt, Matthew J.; Myers, Robert W.; Gurnett, Anne M.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 229 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007042	A1	20010201	WO 2000-US19627	20000719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1204411	A1	20020515	EP 2000-947507	20000719
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

Ward 10/10/600392

JP 2003505417	T2 20030212	JP 2001-511926	20000719
PRIORITY APPLN. INFO.:		US 1999-145329P	P 19990723
		WO 2000-US19627	W 20000719
OTHER SOURCE(S) :	MARPAT 134:131817		
GI			



AB Cyclic tetrapeptide compds. I [X = CH₂, CO, CHO_H, alkoxy- or aryloxymethylene, etc., :CH, or not present; Y = (CH₂)_n, where n = 1 or 2; R₁ = H, alkyl, aryl, acyl, CN, CO₂H or ester, carboxamido, etc.; R₂ = (un)substituted alkyl, alkenyl, or alkynyl, (CH₂)_{nii}-O-(CH₂)_{mii}, where nii, mii = 0-7; R₃ = H, halo, OH, alkoxy, aryloxy, etc., alkyl, aryl; R₅ = iso-Pr, sec-butyl; R₆ = O, S, H₂ (with provisos)] derived from apicidin were prepared for therapeutic inhibition of histone deacetylase activity. Thus, treating 300 mg apicidin with 18 mg NaBH₄ in MeOH and stirring 4 h at room temperature afforded carbonyl reduction product cyclo(N-O-methyl-L-Trp-L-Ile-D-Pip-L-2-amino-8-hydroxydecanoyl) (pip = pipecolic acid residue).

IC ICM A61K031-395

ICS A61K038-12; C07D257-10; C07K005-12

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s) : 7

IT 189337-30-2P	189337-32-4P	312956-80-2P	312956-81-3P	312956-82-4P
312956-83-5P	312956-86-8P	312956-88-0P	312956-90-4P	312956-91-5P
312956-92-6P	312956-95-9P	312956-96-0P	312956-97-1P	312957-00-9P
312957-05-4P	314058-15-6P	314058-18-9P	314058-19-0P	
314058-20-3P	314058-22-5P	314058-23-6P	314058-24-7P	
314058-27-0P	315189-83-4P	315189-84-5P	315189-87-8P	315189-92-5P
315189-93-6P	315189-94-7P	315189-95-8P	315189-96-9P	315189-97-0P
315189-99-2P	315190-03-5P	315190-04-6P	315190-05-7P	315190-06-8P
315190-07-9P	315190-11-5P	315190-12-6P	315190-13-7P	315190-14-8P
321798-41-8P	321798-61-2P	321798-68-9P	321798-73-6P	321798-87-2P
322000-66-8P	322000-67-9P	322000-68-0P	322000-69-1P	
322000-70-4P	322000-72-6P	322000-73-7P	322000-74-8P	322000-75-9P
322000-76-0P	322000-80-6P	322000-82-8P	322000-84-0P	322000-86-2P
322000-87-3P	322000-88-4P	322000-89-5P	322000-91-9P	322000-92-0P
322000-93-1P	322000-94-2P	322000-95-3P	322000-97-5P	322000-98-6P
322000-99-7P	322001-00-3P	322001-01-4P	322001-03-6P	322001-05-8P
322001-07-0P	322001-09-2P	322001-12-7P	322001-13-8P	322001-15-0P
322001-18-3P	322001-19-4P	322001-23-0P	322001-25-2P	322001-26-3P
322001-29-6P	322001-31-0P	322001-32-1P	322001-33-2P	322001-34-3P
322001-35-4P	322001-36-5P	322001-39-8P	322001-41-2P	322001-42-3P
322001-44-5P	322001-45-6P	322001-46-7P	322001-47-8P	322001-48-9P
322001-50-3P	322001-51-4P	322001-52-5P	322001-53-6P	322001-54-7P
322001-55-8P	322001-56-9P	322001-59-2P	322001-60-5P	322001-61-6P
322001-62-7P	322001-63-8P	322001-64-9P	322001-65-0P	322001-66-1P
322001-67-2P	322001-70-7P	322001-71-8P	322001-73-0P	322001-74-1P

Ward 10/10/600392

322001-75-2P 322001-76-3P 322001-77-4P 322001-78-5P
322001-79-6P 322001-80-9P 322001-81-0P 322001-82-1P
322001-83-2P 322001-84-3P 322001-85-4P 322001-86-5P 322001-87-6P
322001-88-7P 322001-92-3P 322001-94-5P 322001-95-6P 322001-96-7P
322002-00-6P 322002-01-7P 322002-02-8P 322002-03-9P 322002-04-0P
322002-07-3P 322002-09-5P 322002-10-8P 322002-11-9P 322002-12-0P
322002-13-1P 322002-14-2P 322002-15-3P 322002-16-4P 322002-17-5P
322002-18-6P 322411-12-1P 322411-13-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of apicidin-derived cyclic tetrapeptides)

IT 314058-20-3P 322000-66-8P 322000-67-9P
322001-77-4P 322001-78-5P 322001-79-6P
322001-80-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of apicidin-derived cyclic tetrapeptides)

RN 314058-20-3 CAPPLUS

CN Cyclo[(2S)-2-amino-8-methylenedecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 322000-66-8 CAPPLUS

CN Cyclo[(2S)-2-amino-8-(hydroxyimino)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 322000-67-9 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(phenylmethoxy)imino]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 322001-77-4 CAPLUS

CN Cyclo[(2S)-2-amino-8-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]hydrazono]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl](9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

Ward 10/10/600392

PAGE 1-A




PAGE 2-A



RN 322001-78-5 CAPLUS

CN Cyclo[(2S)-2-amino-8-[(carboxymethoxy)imino]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 322001-79-6 CAPLUS

CN Cyclo[(2S)-2-amino-8-(methoxyimino)decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinocarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 322001-80-9 CAPLUS


CN Cyclo[(2S)-2-amino-8-[[4-(2,3,6,7,12,13,16,17-octahydro-1H,5H,11H,15H-xantheno[2,3,4-ij:5,6,7-i'j']diquinolizin-18-iium-9-yl)-3-sulfophenyl]sulfonyl]hydrazone]decanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinocarbonyl], inner salt (9CI) (CA INDEX NAME)

Ward 10/10/600392

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:805815 CAPLUS
DOCUMENT NUMBER: 134:56953
TITLE: Design and synthesis of histone deacetylase inhibitors: the development of apicidin transition state analogs
AUTHOR(S): Colletti, Steven L.; Myers, Robert W.; Darkin-Rattray, Sandra J.; Schmatz, Dennis M.; Fisher, Michael H.; Wyvratt, Matthew J.; Meinke, Peter T.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Merck and Co., Inc., Rahway, NJ, 07065, USA

Ward 10/10/600392

SOURCE: Tetrahedron Letters (2000), 41(41), 7837-7841
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:56953

AB A four step degradation of the C8 Et ketone of apicidin provided a route to the C6 aldehyde intermediate and several mechanism-based transition state inhibitors of histone deacetylase. The compds. generated herein delineate the significance of apicidin's side chain, highlighted by the high affinity C8 aldehyde and C8-keto-9,10-epoxide analogs of apicidin.

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1

IT 312956-88-0P 312956-97-1P 314058-18-9P 314058-19-0P

314058-20-3P 314058-23-6P 314058-24-7P 314058-26-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of apicidin transition state analogs as histone deacetylase inhibitors)

IT 314058-20-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of apicidin transition state analogs as histone deacetylase inhibitors)

RN 314058-20-3 CAPLUS

CN Cyclo[(2S)-2-amino-8-methylenedecanoyl-1-methoxy-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>